Pulse Biosciences, Inc. (PLSE) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
3957 Point Eden Way
Miami, CA 94545
United States of America (the)
Phone
510 906 4600
Sector
Healthcare
Industry
Medical - Instruments & Supplies
Employees
75
First IPO Date
May 18, 2016
| Name | Title | Pay | Year Born |
| Paul Arthur LaViolette | President, Chief Executive Officer & Co-Chairman of the Board | 765,068 | 1958 |
| Jon Skinner | Chief Financial Officer | 459,898 | 1986 |
| Darrin R. Uecker | Chief Technology Officer & Director | 869,889 | 1966 |
| David Kenigsberg | Chief Medical Officer | 0 | N/A |
| Gansevoort Dunnington | Chief Medical Officer | 0 | N/A |
| Niv Ad | Chief Science Officer of Cardiac Surgery | 0 | N/A |
| David Danitz | Senior Vice President of Engineering | 0 | N/A |
| Kenneth Stratton | General Counsel & Corporate Secretary | 0 | 1969 |
| Steven T. Weber | Vice President of Accounting, Principal Accounting Officer & Global Corporate Controller | 0 | 1976 |
| Liane Teplitsky | Chief Operating Officer | 0 | 1977 |
| Patty Perla | Vice President of Human Resources | 0 | N/A |
Pulse Biosciences, Inc. is an innovative firm specializing in bioelectric medicine. Their primary offering is the CellFX System, a sophisticated, console-based platform that is precisely controlled via software. This system utilizes its proprietary Nano-Pulse Stimulation technology to deliver extremely brief, nanosecond-duration electrical pulses. This advanced method is designed to selectively eliminate target cells without thermal damage, effectively safeguarding adjacent non-cellular tissue. The CellFX System is applied in the treatment of various medical conditions. The company, originally incorporated in 2014 as Electroblate, Inc., officially became Pulse Biosciences, Inc. in December 2015. Its corporate headquarters are situated in Hayward, California.